These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11090641)

  • 1. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
    Koga K; Kurokawa M; Ochi M; Nakamura J; Kuwana Y
    Eur J Pharmacol; 2000 Nov; 408(3):249-55. PubMed ID: 11090641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
    Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
    Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
    Bibbiani F; Oh JD; Petzer JP; Castagnoli N; Chen JF; Schwarzschild MA; Chase TN
    Exp Neurol; 2003 Nov; 184(1):285-94. PubMed ID: 14637099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
    Fenu S; Pinna A; Ongini E; Morelli M
    Eur J Pharmacol; 1997 Feb; 321(2):143-7. PubMed ID: 9063681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.
    Kanda T; Shiozaki S; Shimada J; Suzuki F; Nakamura J
    Eur J Pharmacol; 1994 May; 256(3):263-8. PubMed ID: 8045270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.
    Haapalinna A; Leino T; Heinonen E
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):342-51. PubMed ID: 14566451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
    Petzer JP; Steyn S; Castagnoli KP; Chen JF; Schwarzschild MA; Van der Schyf CJ; Castagnoli N
    Bioorg Med Chem; 2003 Apr; 11(7):1299-310. PubMed ID: 12628657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain.
    Aoyama S; Koga K; Mori A; Miyaji H; Sekine S; Kase H; Uchimura T; Kobayashi H; Kuwana Y
    Brain Res; 2002 Oct; 953(1-2):119-25. PubMed ID: 12384245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
    Matsuya T; Takuma K; Sato K; Asai M; Murakami Y; Miyoshi S; Noda A; Nagai T; Mizoguchi H; Nishimura S; Yamada K
    J Pharmacol Sci; 2007 Mar; 103(3):329-32. PubMed ID: 17341841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets.
    Kanda T; Tashiro T; Kuwana Y; Jenner P
    Neuroreport; 1998 Aug; 9(12):2857-60. PubMed ID: 9760134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
    Fuzzati-Armentero MT; Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti G; Blandini F; Baqi Y; Müller CE; Volpini R; Costa G; Simola N; Pinna A
    J Neurochem; 2015 Aug; 134(4):740-7. PubMed ID: 25962878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
    Xiao D; Bastia E; Xu YH; Benn CL; Cha JH; Peterson TS; Chen JF; Schwarzschild MA
    J Neurosci; 2006 Dec; 26(52):13548-55. PubMed ID: 17192438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
    Grondin R; Bédard PJ; Hadj Tahar A; Grégoire L; Mori A; Kase H
    Neurology; 1999 May; 52(8):1673-7. PubMed ID: 10331698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.